プラズマ動脈静脈性cGMPの差異は,心不全の患者における窒素耐性の有用な指標として用いられる
T Tsutamoto1, M Kinoshita, Y Ohbayashi
1First Department of Internal Medicine, Shiga University of Medical Science, Otsu, Japan.
Circulation
|August 1, 1994
まとめ
プラズマ動脈静脈のcGMP生成は,ニトログリセリンを効果的に示しています.
科学分野:
- 心血管生理学 心血管の生理学
- 薬理学 薬理学とは
背景:
- 閉塞性心不全 (CHF) は,複雑な血液動力学的課題を提示しています.
- ニトログリセリン (GTN) は,CHFの治療に使用される一般的な血管拡張剤です.
- ニートレアントレランスは,GTNの長期的な有効性を制限する可能性があります.
研究 の 目的:
- ニトログリセリン (GTN) の血動脈静脈循環グアノシンモノフォスファート (cGMP) 産生への影響を調査する.
- 閉塞性心不全 (CHF) 患者におけるGTNの血液動力学的効果を比較する.
- 酸塩耐性のバイオマーカーとしての血動脈静脈性cGMP生成の有用性を評価する.
主な方法:
- 14人のCHF患者のGTN輸注前と後のプラズマcGMP,心房ナトリウレチンペプチド,および血液動力学的パラメータの測定.
- cGMP生産に対する効果を評価するために,用量依存のGTN注入.
- 輸血後の12時間および24時間の血動的耐性およびcGMP生成の評価.
主要な成果:
- GTNの注入は,血動脈静脈のcGMPの産生を,用量依存的に増加させた.
- 肺毛細血管のの圧力が低下し,動脈静脈のcGMP産生が増加したとの間に正の相関が観察されました.
- ヘモダイナミック・トレランスと衰弱した動脈静脈系cGMPの産生は,12時間および24時間後に観察された.
結論:
- 血動脈静脈におけるcGMPの差異は,GTNの血管拡張作用の臨床指標として機能する.
- この測定は,CHF患者の窒素耐性をモニタリングするための貴重なツールです.
さらに関連する動画
関連する概念動画
01:28Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...